A key factor to the successful treatment of HIV is good adherence to antiretroviral therapy (ART). We developed a pharmacist-managed adherence clinic and designed a study to assess the impact of the adherence interventions by measuring the proportion of patients with 95% or greater adherence to ART before and after referral to the program. HIV providers referred patients with adherence problems to a pharmacist-managed adherence clinic. Interventions included scheduled clinic visits with the HIV Clinical Pharmacist and monthly refill reminders from pharmacy staff members over a 6-month period. Those aged 18–75, prescribed an ART regimen for a minimum of 3 months, and who filled their medications exclusively at the clinic pharmacy were eligible for study participation. The Proportion of Days Covered (PDC) served as a surrogate marker of overall adherence. A total of 34 patients were referred to the pharmacy clinic for adherence counseling, of whom 28 enrolled in the study. The proportion of participants with 95% or greater adherence to their ART regimen increased from 7% at baseline to 32% postintervention (p = 0.01). A subanalysis of the PDC revealed an overall increase from a baseline adherence mean of 60% to 81% postintervention (p < 0.0001). There was a notable trend toward an increase in the proportion of participants with an undetectable HIV-1 viral load (58–73%, baseline and postintervention, respectively, p = 0.10), but no statistically significant improvement in CD4 cell count. Clinical pharmacy interventions improved overall adherence to ART regimens in these patients with HIV.
Get full access to this article
View all access options for this article.
References
1.
KitahataMM, ReedSD, DillinghamPWet al.Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS, 2004; 15:803–810.
2.
GolinCE, LiuH, HaysRDet al.A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med, 2002; 17:756–765.
3.
AtkinsonMJ, PetrozzinoJJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care and STDs, 2009; 23:903–914.
4.
PatersonDL, SwindellsS, MohrJet al.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med, 2000; 133:21–30.
5.
ArnstenJH, DemasPA, GrantRWet al.Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med, 2002; 17:377–381.
6.
BangsbergDR, HechtFM, CharleboisEDet al.Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 2000; 14:357–366.
7.
MaggioloF, RavasioL, RipamontiDet al.Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis, 2005; 40:158–163.
8.
GulickRM. Adherence to antiretroviral therapy: How much is enough?Clin Infect Dis, 2006; 43:942–944.
9.
GrossR, YipB, WoodEet al.Boosted protease inhibitors are more forgiving of suboptimal adherence than non-boosted protease inhibitors or nonucleoside reverse transcriptase inhibitors [Abstract 533]Denver, CO, 13th Conference on Retroviruses and Opportunistic Infections, February 5–8, 2006.
10.
ShuterJ, SarloJA, KanmazTJ, RodeRA, ZingmanBS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%J Acquir Immune Defic Syndr, 2007; 45:4–8.
11.
McKinnelJA, WilligJH, WestfallAOet al.Antiretroviral prescribing patterns in treatment-naïve patients in the United States. AIDS Patient Care STDs, 2010; 24:79–85
12.
ShuterJ. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother, 2008; 61:769–773.
13.
BissonGP, RowhA, WeinsteinRet al.Antiretroviral failure despite high levels of adherence: Discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr, 2008; 49:107–110.
14.
BangsbergDR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis, 2006; 43:939–941.
15.
LimaVD, HarriganR, MurrayMet al.Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS, 2008; 22:2371–2380.
16.
SimoniJM, KurthAE, PearsonCR, PantaloneDW, MerrillJO, FrickPA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav, 2006; 10:227–245.
17.
NieuwkerkPT, OortFJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. J Acquir Immune Defic Syndr, 2005; 38:445–448.
18.
LiechtyCA, AlexanderCS, HarriganPRet al.Are untimed antiretroviral drug levels useful predictors of adherence behavior?AIDS, 2004; 18:127–129.
19.
WoodE, HoggRS, YipB, HarriganPR, O'ShaughnessyMV, MontanerJS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med., 2003; 139:810–816.
20.
SclarDA, ChinA, SkaerTL, OkamotoMP, NakahiroRK, GillMA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther, 1991; 13:489–495.
21.
YangY, ThumulaV, PacePF, BanahanBF3rd, WilkinNE, LobbWB. Nonadherence to angiotensinconverting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs. J Am Pharm Assoc, 2003; 50:527–531.
22.
CambianoV, LampeFC, RodgerAJet al.Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med, 2010; 11:216–224.
23.
MannheimerSB, MorseE, MattsJPet al.Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr, 2006; 43,Suppl 1:S41–47.
24.
GuerraultMN, LeclercC, LangevinS, Merian-BrosseL, BrossardD, WelkerY. [Study of the usefulness of pharmacist consultations for patients on antiretroviral regimens]Presse Med, 2005; 34:1563–1570.
25.
Cantwell-McNelisK, JamesCW. Role of clinical pharmacists in outpatient HIV clinics. Am J Health Syst Pharm, 2002; 59:447–452.
26.
Improving the prevention and treatment of HIV/AIDS through pharmacist interventions. GalD. The International Network for Pharmacists on HIV/AIDS. International Pharmaceutical Federation (FIP), 2004.
27.
KnobelH, CarmonaA, LopezJLet al.[Adherence to very active antiretroviral treatment: Impact of individualized assessment]Enferm Infecc Microbiol Clin, 1999; 17:78–81.
28.
McPherson-BakerS, MalowRM, PenedoF, JonesDL, SchneidermanN, KlimasNG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care, 2000; 12:399–404.
29.
SimoniJM, FrickPA, PantaloneDW, TurnerBJ. Antiretroviral adherence interventions: A review of current literature and ongoing studies. Top HIV Med, 2003; 11:185–198.
30.
VAMC. Pharmacist Counseling, use of compliance tool: Does it improve outcomes in an HIV population?Formulary, 1998; 33:1144.
31.
AtkinsonMJ, PetrozzinoJJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDs, 2009; 23:903–914.
32.
HirschJD, RosenquistA, BestBM, MillerTA, GilmerTP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm, 2009; 15:32–41.
33.
RuedaS, Park-WyllieLY, BayoumiAet al.Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. The Cochrane Database Syst Rev, 2006; 3:CD001442.
34.
HugenPW, BurgerDM, KoopmansPPet al.Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci, 2002; 24:83–86.
35.
PellegrinI, BreilhD, MontestrucFet al.Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study)AIDS, 2002; 16:1331–1340.
36.
ZhouXJ, HavlirDV, RichmanDDet al.Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1–infected patients. AIDS, 2000; 14:2869–2876.
37.
MaA, ChenDM, ChauFM, SaberiP. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care, 2010; 1–6.
